| 3465 | Humans |
| 2955 | SARS Virus |
| 2059 | Severe Acute Respiratory Syndrome |
| 2025 | Animals |
| 737 | Coronavirus Infections |
| 693 | Female |
| 672 | Viral Envelope Proteins |
| 661 | Spike Glycoprotein, Coronavirus |
| 600 | Disease Outbreaks |
| 593 | Male |
| 583 | Mice |
| 575 | Membrane Glycoproteins |
| 536 | Antibodies, Viral |
| 525 | Molecular Sequence Data |
| 503 | Cell Line |
| 498 | Antiviral Agents |
| 484 | Coronavirus |
| 469 | Chlorocebus aethiops |
| 469 | Amino Acid Sequence |
| 454 | Adult |
| 453 | Viral Proteins |
| 413 | Virus Replication |
| 407 | Vero Cells |
| 397 | RNA, Viral |
| 384 | Pneumonia, Viral |
| 378 | China |
| 372 | Middle Aged |
| 367 | Betacoronavirus |
| 303 | Models, Molecular |
| 298 | Pandemics |
| 296 | Viral Vaccines |
| 285 | Genome, Viral |
| 276 | Reverse Transcriptase Polymerase Chain Reaction |
| 273 | Communicable Diseases, Emerging |
| 263 | Nucleocapsid Proteins |
| 258 | Protein Binding |
| 239 | Base Sequence |
| 236 | Protein Structure, Tertiary |
| 236 | Phylogeny |
| 235 | Aged |
| 225 | Lung |
| 222 | Influenza, Human |
| 221 | Recombinant Proteins |
| 220 | Mice, Inbred BALB C |
| 206 | Chiroptera |
| 193 | Enzyme-Linked Immunosorbent Assay |
| 187 | Structure-Activity Relationship |
| 184 | Peptidyl-Dipeptidase A |
| 183 | Cysteine Endopeptidases |
| 183 | Adolescent |
| 179 | Middle East Respiratory Syndrome Coronavirus |
| 174 | Zoonoses |
| 173 | Binding Sites |
| 169 | Receptors, Virus |
| 169 | Mutation |
| 162 | Viral Nonstructural Proteins |
| 161 | Disease Models, Animal |
| 160 | Neutralization Tests |
| 160 | Global Health |
| 159 | Sensitivity and Specificity |
| 156 | Protein Conformation |
| 155 | Time Factors |
| 155 | Hong Kong |
| 150 | Virus Diseases |
| 146 | Murine hepatitis virus |
| 144 | Immunoglobulin G |
| 142 | Child |
| 140 | Antibodies, Monoclonal |
| 127 | Viral Matrix Proteins |
| 127 | Sequence Alignment |
| 126 | Drug Design |
| 123 | Crystallography, X-Ray |
| 121 | Infection Control |
| 121 | Antigens, Viral |
| 119 | Polymerase Chain Reaction |
| 117 | Disease Reservoirs |
| 116 | Virus Internalization |
| 114 | Cells, Cultured |
| 111 | United States |
| 109 | Sequence Analysis, DNA |
| 108 | Travel |
| 108 | Communicable Disease Control |
| 106 | RNA Replicase |
| 106 | Host-Pathogen Interactions |
| 105 | Risk Factors |
| 105 | DNA, Viral |
| 104 | Protease Inhibitors |
| 101 | Peptides |
| 101 | Blotting, Western |
| 101 | Aged, 80 and over |
| 99 | Respiratory Tract Infections |
| 99 | Open Reading Frames |
| 99 | Escherichia coli |
| 98 | Cricetinae |
| 98 | Cloning, Molecular |
| 95 | Child, Preschool |
| 94 | Public Health |
| 94 | Molecular Structure |
| 94 | Cytokines |
| 93 | Evolution, Molecular |
| 92 | Gene Expression |
| 91 | Sequence Homology, Amino Acid |
| 90 | World Health Organization |
| 88 | Genetic Vectors |
| 87 | Influenza A Virus, H1N1 Subtype |
| 85 | Kinetics |
| 84 | HIV-1 |
| 84 | Cross Infection |
| 82 | Virulence |
| 82 | Recombinant Fusion Proteins |
| 82 | Infant |
| 82 | Computational Biology |
| 80 | Protein Structure, Secondary |
| 79 | Models, Biological |
| 79 | DNA Primers |
| 78 | Retrospective Studies |
| 77 | Immunity, Innate |
| 77 | Gene Expression Regulation, Viral |
| 75 | Transfection |
| 74 | Genetic Variation |
| 74 | Dose-Response Relationship, Drug |
| 73 | Viruses |
| 73 | Influenza A virus |
| 72 | Young Adult |
| 72 | Taiwan |
| 72 | HeLa Cells |
| 71 | RNA, Messenger |
| 71 | Epitopes |
| 68 | Swine |
| 67 | Influenza A Virus, H5N1 Subtype |
| 66 | Vaccination |
| 66 | Genes, Viral |
| 66 | Computer Simulation |
| 65 | Population Surveillance |
| 65 | Membrane Fusion |
| 64 | Viral Load |
| 64 | Feces |
| 64 | Epithelial Cells |
| 64 | Amino Acid Substitution |
| 63 | Species Specificity |
| 63 | Recombination, Genetic |
| 63 | Mice, Inbred C57BL |
| 63 | Infectious Disease Transmission, Patient-to-Professional |
| 63 | Apoptosis |
| 61 | Vaccines, DNA |
| 61 | Plasmids |
| 61 | Canada |
| 60 | Risk Assessment |
| 60 | Clinical Laboratory Techniques |
| 59 | Singapore |
| 58 | Coronavirus 229E, Human |
| 57 | Cell Membrane |
| 56 | Rabbits |
| 56 | Microbial Sensitivity Tests |
| 56 | Health Personnel |
| 56 | HEK293 Cells |
| 56 | Disease Transmission, Infectious |
| 56 | Antibodies, Neutralizing |
| 55 | Reproducibility of Results |
| 55 | Catalytic Domain |
| 54 | Virion |
| 54 | Contact Tracing |
| 54 | Cell Line, Tumor |
| 54 | Algorithms |
| 53 | Viral Fusion Proteins |
| 53 | Substrate Specificity |
| 53 | RNA, Small Interfering |
| 53 | Quarantine |
| 53 | Immunization |
| 52 | Signal Transduction |
| 52 | Ribavirin |
| 52 | Interferon-gamma |
| 51 | Transcription, Genetic |
| 51 | Peptide Hydrolases |
| 51 | Cytopathogenic Effect, Viral |
| 50 | Interferon Type I |
| 50 | Dimerization |
| 49 | Rats |
| 49 | Mutagenesis, Site-Directed |
| 49 | CD8-Positive T-Lymphocytes |
| 48 | Viral Structural Proteins |
| 48 | Enzyme Inhibitors |
| 48 | Diagnosis, Differential |
| 47 | Protein Multimerization |
| 47 | Inhibitory Concentration 50 |
| 47 | Cats |
| 46 | Vaccines, Synthetic |
| 46 | Peptide Fragments |
| 46 | Gene Expression Regulation |
| 46 | Flow Cytometry |
| 46 | Epitope Mapping |
| 46 | Endopeptidases |
| 46 | Drug Evaluation, Preclinical |
| 46 | Coronaviridae |
| 45 | Microscopy, Electron |
| 45 | DNA, Complementary |
| 45 | Amino Acid Motifs |
| 44 | Severity of Illness Index |
| 44 | Cross Reactions |
| 44 | Anti-HIV Agents |
| 43 | Membrane Proteins |
| 43 | Interferons |
| 43 | Immunohistochemistry |
| 42 | Virus Assembly |
| 42 | T-Lymphocytes |
| 42 | Oligonucleotide Array Sequence Analysis |
| 42 | Interferon-alpha |
| 42 | Gene Expression Profiling |
| 42 | Antibody Specificity |
| 41 | Real-Time Polymerase Chain Reaction |
| 40 | Vaccines, Inactivated |
| 40 | Sequence Deletion |
| 40 | Prognosis |
| 40 | Immunoglobulin M |
| 40 | Conserved Sequence |
| 40 | Cluster Analysis |
| 40 | Carboxypeptidases |
| 39 | Patient Isolation |
| 39 | Nucleocapsid |
| 39 | Incidence |
| 39 | Circular Dichroism |
| 38 | Viverridae |
| 38 | Transmissible gastroenteritis virus |
| 38 | Influenza in Birds |
| 38 | Infectious bronchitis virus |
| 38 | Fluorescent Antibody Technique |
| 38 | Communicable Diseases |
| 38 | Chickens |
| 38 | Cell Fusion |
| 38 | Birds |
| 38 | Adjuvants, Immunologic |
| 37 | Treatment Outcome |
| 37 | Peptide Library |
| 37 | Fluorescent Antibody Technique, Indirect |
| 36 | Protein Processing, Post-Translational |
| 36 | Protein Folding |
| 36 | Molecular Docking Simulation |
| 36 | Macaca mulatta |
| 36 | Genotype |
| 36 | Cytoplasm |
| 36 | Cattle |
| 35 | Survival Analysis |
| 35 | Models, Statistical |
| 35 | Hepacivirus |
| 35 | HIV Infections |
| 35 | Green Fluorescent Proteins |
| 35 | Fever |
| 35 | Epitopes, T-Lymphocyte |
| 35 | Electrophoresis, Polyacrylamide Gel |
| 35 | Drug Discovery |
| 35 | Dogs |
| 35 | CD4-Positive T-Lymphocytes |
| 34 | T-Lymphocytes, Cytotoxic |
| 34 | Infant, Newborn |
| 34 | Endoplasmic Reticulum |
| 34 | Cell Adhesion Molecules |
| 34 | Case-Control Studies |
| 33 | Reverse Transcriptase Inhibitors |
| 33 | Orthomyxoviridae |
| 33 | Nucleic Acid Conformation |
| 33 | International Cooperation |
| 33 | Interferon-beta |
| 33 | Dendritic Cells |
| 32 | Serologic Tests |
| 32 | Seroepidemiologic Studies |
| 32 | RNA Viruses |
| 32 | Models, Genetic |
| 32 | Mice, Transgenic |
| 32 | Macrophages |
| 32 | Glycosylation |
| 32 | Follow-Up Studies |
| 32 | Epidemics |
| 32 | COS Cells |
| 32 | Antibody Formation |
| 31 | Software |
| 31 | RNA |
| 31 | Protein Structure, Quaternary |
| 31 | Promoter Regions, Genetic |
| 31 | Pregnancy |
| 31 | Hospitalization |
| 31 | Glycoproteins |
| 31 | Cell Proliferation |
| 31 | Cell Nucleus |
| 31 | Biomedical Research |
| 30 | Temperature |
| 30 | Receptors, Cell Surface |
| 30 | Prevalence |
| 30 | Ontario |
| 30 | Magnetic Resonance Spectroscopy |
| 30 | Genomics |
| 29 | Virology |
| 29 | Vaccines, Attenuated |
| 29 | Respiratory Distress Syndrome, Adult |
| 29 | RNA Interference |
| 29 | Phosphorylation |
| 29 | Nasopharynx |
| 29 | Microscopy, Fluorescence |
| 29 | Microscopy, Confocal |
| 29 | Hydrogen-Ion Concentration |
| 29 | Golgi Apparatus |
| 29 | Genes, Reporter |
| 28 | Virus Attachment |
| 28 | Ubiquitin |
| 28 | Models, Theoretical |
| 28 | Methyltransferases |
| 28 | Metapneumovirus |
| 28 | Hydrogen Bonding |
| 28 | Hemorrhagic Fever, Ebola |
| 28 | HIV Reverse Transcriptase |
| 28 | Ebolavirus |
| 28 | Coronavirus OC43, Human |
| 28 | Age Factors |
| 27 | Two-Hybrid System Techniques |
| 27 | Papain |
| 27 | Hospitals |
| 27 | Disease Progression |
| 27 | DNA Helicases |
| 27 | Cohort Studies |
| 26 | Tomography, X-Ray Computed |
| 26 | Orthomyxoviridae Infections |
| 26 | Liver |
| 26 | Kidney |
| 26 | Immunity, Cellular |
| 26 | Health Knowledge, Attitudes, Practice |
| 26 | Down-Regulation |
| 26 | Disease Susceptibility |
| 26 | Coronaviridae Infections |
| 26 | Animals, Wild |
| 26 | Administration, Intranasal |
| 25 | Surveys and Questionnaires |
| 25 | Respiratory System |
| 25 | Protein Transport |
| 25 | Protein Interaction Mapping |
| 25 | Molecular Epidemiology |
| 25 | Ligands |
| 25 | Ferrets |
| 25 | Enzyme Activation |
| 25 | Centers for Disease Control and Prevention, U.S. |
| 24 | Vaccinia virus |
| 24 | Seasons |
| 24 | RNA-Binding Proteins |
| 24 | Practice Guidelines as Topic |
| 24 | Polymorphism, Single Nucleotide |
| 24 | Point Mutation |
| 24 | Nuclear Magnetic Resonance, Biomolecular |
| 24 | Molecular Conformation |
| 24 | Interferon Regulatory Factor-3 |
| 24 | Immunization, Passive |
| 24 | Hydrophobic and Hydrophilic Interactions |
| 24 | HIV |
| 24 | Cysteine Proteinase Inhibitors |
| 24 | Cell Survival |
| 24 | Catalysis |
| 24 | Antigens, CD |
| 23 | Viral Tropism |
| 23 | Up-Regulation |
| 23 | United Kingdom |
| 23 | Thermodynamics |
| 23 | Serine Endopeptidases |
| 23 | Research |
| 23 | Protein Interaction Domains and Motifs |
| 23 | Pneumonia |
| 23 | Occupational Exposure |
| 23 | Nucleic Acid Amplification Techniques |
| 23 | NF-kappa B |
| 23 | Middle East |
| 23 | Italy |
| 23 | Interleukin-6 |
| 23 | Immunologic Memory |
| 23 | Immune Evasion |
| 23 | History, 21st Century |
| 23 | DNA |
| 23 | Cough |
| 23 | Chemokines |
| 22 | Sequence Analysis, Protein |
| 22 | Risk |
| 22 | Radiography, Thoracic |
| 22 | Pregnancy Complications, Infectious |
| 22 | Pharynx |
| 22 | Oligopeptides |
| 22 | Molecular Weight |
| 22 | Macaca fascicularis |
| 22 | Lectins, C-Type |
| 22 | In Vitro Techniques |
| 22 | Immunoprecipitation |
| 22 | Europe |
| 22 | Drug Therapy, Combination |
| 22 | Coronavirus, Feline |
| 22 | Adenoviridae |
| 21 | Public Health Practice |
| 21 | Mice, Knockout |
| 21 | Internationality |
| 21 | Drugs, Chinese Herbal |
| 21 | Drug Resistance, Viral |
| 21 | Coronavirus, Bovine |
| 21 | Baculoviridae |
| 20 | Trypsin |
| 20 | Sequence Homology, Nucleic Acid |
| 20 | Republic of Korea |
| 20 | Radiography |
| 20 | Pulmonary Alveoli |
| 20 | Protein Biosynthesis |
| 20 | Phenotype |
| 20 | Paramyxoviridae Infections |
| 20 | Lung Diseases |
| 20 | Hydrolysis |
| 20 | Hemagglutinins, Viral |
| 20 | Health Policy |
| 20 | Gene Deletion |
| 20 | Frameshifting, Ribosomal |
| 20 | Exoribonucleases |
| 20 | Disaster Planning |
| 20 | Brain |
| 20 | Bioterrorism |
| 20 | Biomarkers |
| 20 | Bacterial Infections |
| 20 | Asia |
| 20 | Anti-Bacterial Agents |
| 20 | Aerosols |
| 19 | Virus Inactivation |
| 19 | Surface Plasmon Resonance |
| 19 | Spleen |
| 19 | Saudi Arabia |
| 19 | Protein Subunits |
| 19 | Protein Domains |
| 19 | Mutagenesis |
| 19 | Luciferases |
| 19 | In Situ Hybridization |
| 19 | Immunoglobulin A |
| 19 | Cathepsin L |
| 19 | Anti-Inflammatory Agents |
| 19 | Air Microbiology |
| 18 | Solubility |
| 18 | Proteolysis |
| 18 | Prospective Studies |
| 18 | Probability |
| 18 | Polymorphism, Genetic |
| 18 | Molecular Dynamics Simulation |
| 18 | Models, Chemical |
| 18 | Masks |
| 18 | Internet |
| 18 | Hepatitis B virus |
| 18 | Genetic Predisposition to Disease |
| 18 | Endosomes |
| 18 | Disease Notification |
| 18 | Dipeptidyl Peptidase 4 |
| 18 | Cysteine |
| 18 | Crystallization |
| 18 | Coronavirus NL63, Human |
| 18 | Convalescence |
| 18 | Caco-2 Cells |
| 18 | Autopsy |
| 18 | 5' Untranslated Regions |
| 17 | Vietnam |
| 17 | Ubiquitination |
| 17 | Spodoptera |
| 17 | Spectrometry, Fluorescence |
| 17 | Porcine epidemic diarrhea virus |
| 17 | Personnel, Hospital |
| 17 | Molecular Diagnostic Techniques |
| 17 | Mass Spectrometry |
| 17 | Genome |
| 17 | Electrophoretic Mobility Shift Assay |
| 17 | Disinfection |
| 17 | Disease Vectors |
| 17 | Clinical Trials as Topic |
| 17 | CHO Cells |
| 17 | Biosensing Techniques |
| 17 | Amino Acids |
| 16 | Virus Shedding |
| 16 | Vaccines, Subunit |
| 16 | Tumor Cells, Cultured |
| 16 | Survival Rate |
| 16 | Static Electricity |
| 16 | Sequence Analysis, RNA |
| 16 | Respiratory Syncytial Viruses |
| 16 | Reagent Kits, Diagnostic |
| 16 | Proteomics |
| 16 | Proteome |
| 16 | Poultry |
| 16 | Occupational Diseases |
| 16 | Microscopy, Electron, Transmission |
| 16 | Ion Channels |
| 16 | Information Dissemination |
| 16 | Influenza Vaccines |
| 16 | Hybridomas |
| 16 | Epidemiological Monitoring |
| 16 | Endocytosis |
| 16 | Dengue Virus |
| 16 | Community-Acquired Infections |
| 16 | Cathepsins |
| 16 | Biological Evolution |
| 15 | West Nile virus |
| 15 | Viral Plaque Assay |
| 15 | Ultraviolet Rays |
| 15 | Tumor Necrosis Factor-alpha |
| 15 | Swine Diseases |
| 15 | Small Molecule Libraries |
| 15 | Sequence Homology |
| 15 | Respiratory Mucosa |
